FDA Clarifies User Fee Refund Policy, MDUFMA Performance Goals
This article was originally published in The Gray Sheet
Executive Summary
FDA's adherence to user fee performance goals will be measured by "FDA days"- the amount of time a premarket application is pending at the agency - rather than by total review times, HHS clarifies in a November presentation to Congress
You may also be interested in...
FDA Floats Updated Guidance On User-Fee Refund Rules
User fees paid to FDA by device firms for 30-day notices are not eligible for refunds if a company withdraws the submission, according to a March 13 draft 1guidance
FDA Floats Updated Guidance On User-Fee Refund Rules
User fees paid to FDA by device firms for 30-day notices are not eligible for refunds if a company withdraws the submission, according to a March 13 draft 1guidance
FDA Guidance Aims To Hit MDUFMA Expedited Review Performance Goals
Expedited review status requires manufacturers to make all related scientific and regulatory issues a top priority, according to an FDA guidance document